Ribo Newsroom
-
Ribo's PCSK9-targeting siRNA drug RBD7022 is about to launch Phase III clinical trials in China.Ribo's PCSK9-targeting siRNA drug RBD7022 is about to launch Phase III clinical trials in China.March 2, 2026 -
Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASHRibo entered into an exclusive worldwide license agreement with Madrigal for six pre-clinical siRNA programs for the treatment of MASH.February 11, 2026 -
Recent advances in factor XI (FXI) inhibition are reshaping the landscape of anticoagulation therapyRecent advances in factor XI (FXI) inhibition are reshaping the landscape of anticoagulation therapyFebruary 9, 2026 -
Ribo Receives Phase II Clinical Approval for ApoC3-targeting siRNA drug RBD5044 in ChinaRibo Receives Phase II Clinical Approval for ApoC3-targeting siRNA drug RBD5044 in ChinaJanuary 23, 2026 -
Ribo Life Science (06938.HK) Successfully Lists on the Main Board of the Hong Kong Stock ExchangeRibo Life Science (06938.HK) Successfully Lists on the Main Board of the Hong Kong Stock ExchangeJanuary 9, 2026 -
Ribo Presents Kidney-Targeted Delivery Data at ASN Kidney Week 2025Ribo recently presented a poster at the ASN Kidney Week in Texas, showcasing the kidney-targeted delivery of siRNA using its RiboPepSTAR™ peptide conjugates.December 4, 2025